MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Change in Cash
-$641K
Free Cash flow
$12,481K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
Proceeds from maturities and sal...
Stock-based compensation expense
Accrued liabilities
Others
Negative Cash Flow Breakdown
Purchases of marketable securiti...
Accounts payable
Accounts receivable, net
Others
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Net income (loss)
15,009
-11,295
17,395
7,410
Stock-based compensation expense
12,762
10,690
10,060
10,037
Amortization of intangible assets
563
562
563
562
Non-cash interest expense
480
461
461
449
Net accretion on marketable securities
223
182
-11
551
Other non-cash items, net
-277
-214
-21
-283
Accounts receivable, net
10,786
-1,852
31,113
8,429
Inventory
1,177
14,579
5
5,891
Prepaid expenses and other current assets
2,546
11,728
1,265
1,760
Accounts payable
-11,536
5,613
6,731
-9,288
Accrued liabilities
9,955
20,768
23,452
5,574
Operating lease liabilities
-139
-137
-126
-150
Net cash provided by (used in) operating activities
12,639
2,239
26,185
-1,754
Purchases of marketable securities
65,591
62,153
89,180
68,544
Proceeds from maturities and sales of marketable securities
50,525
50,821
55,001
172,418
Milestone payment for intangible asset
0
-
0
0
Purchases of property and equipment
158
0
0
0
Net cash provided by (used in) investing activities
-15,224
-11,332
-34,179
-25,247
Proceeds from issuance of common stock, net of issuance costs
-
-
0
0
Repayment of long-term debt
-
-
0
-
Proceeds from issuance of common stock upon exercise of stock options
1,361
1,067
2,665
1,476
Proceeds from issuance of common stock pursuant to employee stock purchase plan
1,629
-
1,057
0
Proceeds from issuance of common stock and pre-funded warrants, net of issuance costs
-
-
0
-
Proceeds from issuance of shares under atm, net of issuance costs
-
-
0
-
Payment of debt prepayment penalty
1,000
-
-
-
Net cash provided by financing activities
1,990
1,067
3,722
1,476
Effect of exchange rate changes on cash
-46
-119
59
-95
Net increase (decrease) in cash, cash equivalents, and restricted cash
-641
-8,145
-4,213
-25,620
Cash, cash equivalents, and restricted cash at beginning of period
35,070
43,215
53,721
53,721
Cash, cash equivalents, and restricted cash at end of period
34,429
35,070
43,215
47,428
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Net income (loss)
$15,009K
(194.48%↑ Y/Y)
Proceeds from issuance of
common stock pursuant...
$1,629K
(23.50%↑ Y/Y)
Proceeds from issuance of
common stock upon...
$1,361K
(2131.15%↑ Y/Y)
Stock-based compensation
expense
$12,762K
(21.67%↑ Y/Y)
Accrued liabilities
$9,955K
(-53.11%↓ Y/Y)
Amortization of intangible
assets
$563K
(0.00%↑ Y/Y)
Non-cash interest
expense
$480K
(11.37%↑ Y/Y)
Other non-cash items,
net
-$277K
(20.40%↑ Y/Y)
Net cash provided by
(used in) operating...
$12,639K
(3800.93%↑ Y/Y)
Net cash provided by
financing activities
$1,990K
(44.20%↑ Y/Y)
Canceled cashflow
$26,407K
Canceled cashflow
$1,000K
Net increase
(decrease) in cash, cash...
-$641K
(-103.32%↓ Y/Y)
Canceled cashflow
$14,629K
Proceeds from maturities
and sales of...
$50,525K
Accounts payable
-$11,536K
(-2182.31%↓ Y/Y)
Accounts receivable, net
$10,786K
(-49.29%↓ Y/Y)
Prepaid expenses and
other current assets
$2,546K
(159.21%↑ Y/Y)
Inventory
$1,177K
(327.22%↑ Y/Y)
Net accretion on
marketable securities
$223K
(-67.91%↓ Y/Y)
Operating lease
liabilities
-$139K
(31.86%↑ Y/Y)
Payment of debt
prepayment penalty
$1,000K
Net cash provided by
(used in) investing...
-$15,224K
(-187.38%↓ Y/Y)
Canceled cashflow
$50,525K
Effect of exchange rate
changes on cash
-$46K
(-123.00%↓ Y/Y)
Purchases of marketable
securities
$65,591K
(97.85%↑ Y/Y)
Purchases of property and
equipment
$158K
(102.56%↑ Y/Y)
Buy us a coffee
logo-arcutis (1)-svg
Arcutis Biotherapeutics, Inc. (ARQT)
logo-arcutis (1)-svg
Arcutis Biotherapeutics, Inc. (ARQT)